{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:52:42Z","timestamp":1788292362111,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.radonc.2023.110034","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T07:07:26Z","timestamp":1701068846000},"page":"110034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART)"],"prefix":"10.1016","volume":"190","author":[{"given":"Grace","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Tjong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Cagney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Anh","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Kann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Leeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110034_b0005","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2023.110034_b0010","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2007.10.053","article-title":"Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer","volume":"70","author":"Lagerwaard","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110034_b0015","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2023.110034_b0020","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110034_b0025","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2023.110034_b0030","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"JCO"},{"key":"10.1016\/j.radonc.2023.110034_b0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non\u2013small-cell lung cancer: What we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0040","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2018.07.001","article-title":"The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors","volume":"129","author":"Chang","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.adro.2019.01.002","article-title":"Long-term clinical outcomes and safety profile of SBRT for centrally located NSCLC","volume":"4","author":"Arnett","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0050","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2014.08.008","article-title":"Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy","volume":"90","author":"Modh","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110034_b0055","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.radonc.2011.12.023","article-title":"Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors","volume":"102","author":"Nuyttens","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0060","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1097\/JTO.0b013e31822e71d8","article-title":"Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer","volume":"6","author":"Haasbeek","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2015.09.028","article-title":"Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes","volume":"117","author":"Tekatli","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0070","doi-asserted-by":"crossref","unstructured":"Tekatli H, Giraud N, Van Eekelen R, Lagerwaard FJ, Senan S. Ten years outcomes after SABR in central and ultracentral primary lung tumors. Radiotherapy and Oncology. Published online August 2023:109848. doi:10.1016\/j.radonc.2023.109848.","DOI":"10.1016\/j.radonc.2023.109848"},{"key":"10.1016\/j.radonc.2023.110034_b0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.37549\/ARO1288","article-title":"Actualizing risk-adapted thoracic stereotactic body radiation therapy with MR guidance","volume":"10","author":"Singer","year":"2021","journal-title":"Appl Rad Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0080","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial\u2014A prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0085","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: A systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0090","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cUltracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2020.07.009","article-title":"Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors","volume":"147","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110034_b0100","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0105","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/0284186X.2021.1942545","article-title":"Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy","volume":"60","author":"Lodeweges","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0110","first-page":"737","article-title":"Analysis of toxic effects with antiangiogenic agents plus stereotactic body radiation in ultracentral lung tumors","volume":"5","author":"Wang","year":"2019","journal-title":"J Am Med Assoc Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0115","unstructured":"Dana-Farber Cancer Institute. Stereotactic Magnetic Resonance Guided Radiation Therapy. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04115254. NLM Identifier:NCT04115254."},{"key":"10.1016\/j.radonc.2023.110034_b0120","unstructured":"Dana-Farber Cancer Institute. Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer. In: ClinicalTrials.gov [Internet]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04789486. NLM Identifier:NCT04789486."},{"key":"10.1016\/j.radonc.2023.110034_b0125","doi-asserted-by":"crossref","first-page":"1061854","DOI":"10.3389\/fonc.2023.1061854","article-title":"Adaptive hypofractionted and stereotactic body radiotherapy for lung tumors with real-time MRI guidance","volume":"13","author":"Bryant","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0130","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/j.prro.2021.01.009","article-title":"Development and implementation of an online adaptive stereotactic body radiation therapy workflow for treatment of intracardiac metastasis","volume":"11","author":"Shi","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ijrobp.2019.03.035","article-title":"Role of on-table plan adaptation in MR-guided ablative radiation therapy for central lung tumors","volume":"104","author":"Finazzi","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110034_b0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.110034_b0145","unstructured":"U.S. Department of Health and Human Services. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available at: https:\/\/ctep. cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v 5_Quick_Reference_8.5x11.pdf. Accessed June 15, 2023."},{"key":"10.1016\/j.radonc.2023.110034_b0150","doi-asserted-by":"crossref","unstructured":"Lindberg S, Grozman V, Karlsson K, et al. Expanded HILUS trial - a pooled analysis of risk factors for toxicity from SBRT of central and ultra-central lung tumors. International Journal of Radiation Oncology*Biology*Physics. Published online July 2023:S0360301623044784. doi:10.1016\/j.ijrobp.2023.06.246.","DOI":"10.1016\/j.ijrobp.2023.06.246"},{"key":"10.1016\/j.radonc.2023.110034_b0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110034_b0160","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1756-8722-3-39","article-title":"CyberKnife for hilar lung tumors: report of clinical response and toxicity","volume":"3","author":"Unger","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13014-016-0608-8","article-title":"Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases","volume":"11","author":"Lischalk","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.10.014","article-title":"Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers","volume":"115","author":"Horne","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110034_b0175","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1016\/j.cllc.2018.06.001","article-title":"Ultracentral tumors treated with stereotactic body radiotherapy: Single-institution experience","volume":"19","author":"Raman","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110034_b0180","article-title":"Magnetic resonance-guided stereotactic body radiation therapy\/hypofractionated radiation therapy for metastatic and primary central and ultracentral lung lesions","volume":"4","author":"Sandoval","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.radonc.2023.110034_b0185","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.jtho.2021.06.030","article-title":"The nordic-HILUS trial: Ultracentral lung stereotactic ablative radiotherapy and a narrow therapeutic window","volume":"16","author":"Rosenberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0190","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/cncr.34836","article-title":"Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis","volume":"129","author":"Leeman","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.110034_b0195","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.adro.2018.10.003","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: Results of a phase 1 trial","volume":"4","author":"Henke","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0200","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijrobp.2020.02.025","article-title":"Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors","volume":"107","author":"Finazzi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110034_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.03.011","article-title":"To fly or not to fly: Stereotactic MR-guided adaptive radiotherapy effectively treats ultracentral lung tumors with favorable long-term outcomes","volume":"179","author":"Regnery","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.110034_b0210","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/JTO.0b013e3181858eba","article-title":"Tracheo-esophageal fistula with bevacizumab after mediastinal radiation","volume":"3","author":"Goodgame","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.110034_b0215","unstructured":"Baptist Health South Florida. Study of LUNG Stereotactic Adaptive Ablative Radiotherapy (LUNG STAAR). In: ClinicalTrials.gov [Internet]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04917224. NLM Identifier:NCT04917224."},{"key":"10.1016\/j.radonc.2023.110034_b0220","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: Stereotactic radiation for ultracentral non\u2013small-cell lung cancer\u2014A safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T09:09:43Z","timestamp":1734253783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":44,"alternative-id":["S0167814023093416"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110034","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Widening the therapeutic window for central and ultra-central thoracic oligometastatic disease with stereotactic MR-guided adaptive radiation therapy (SMART)","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110034"}}